Nevro

About:

Nevro provides pain relief solutions for patients suffering from low back pain and other types of chronic pain.

Website: http://www.nevro.com

Twitter/X: nevro_hf10

Top Investors: New Enterprise Associates, Mayo Clinic, MPM Capital, Braidwell, CRG

Description:

Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Total Funding Amount:

$556M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Menlo Park, California, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)nevrocorp.com

Founders:

Konstantinos Alataris

Number of Employees:

1001-5000

Last Funding Date:

2023-11-30

IPO Status:

Public

© 2025 bioDAO.ai